Related Experiment Video
Updated: Jul 29, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Junko Murai1,2,3,4, Michele Ceribelli5, Haiqing Fu1
1Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Abstract:
Schlafen 11 (SLFN11) is an increasingly prominent predictive biomarker and a molecular sensor for a wide range of clinical drugs: topoisomerases, PARP and replication inhibitors, and platinum derivatives. To expand the spectrum of drugs and pathways targeting SLFN11, we ran a high-throughput screen with 1,978 mechanistically annotated, oncology-focused compounds in two isogenic pairs of SLFN11-proficient and -deficient cells (CCRF-CEM and K562). We identified 29 hit compounds that selectively kill SLFN11-proficient cells, including not only previously known DNA-targeting agents, but also the neddylation inhibitor pevonedistat (MLN-4924) and the DNA polymerase α inhibitor AHPN/CD437, which both induced SLFN11 chromatin recruitment. By inactivating cullin-ring E3 ligases, pevonedistat acts as an anticancer agent partly by inducing unscheduled re-replication through supraphysiologic accumulation of CDT1, an essential factor for replication initiation. Unlike the known DNA-targeting agents and AHPN/CD437 that recruit SLFN11 onto chromatin in 4 hours, pevonedistat recruited SLFN11 at late time points (24 hours). While pevonedistat induced unscheduled re-replication in SLFN11-deficient cells after 24 hours, the re-replication was largely blocked in SLFN11-proficient cells. The positive correlation between sensitivity to pevonedistat and SLFN11 expression was also observed in non-isogenic cancer cells in three independent cancer cell databases (NCI-60, CTRP: Cancer Therapeutics Response Portal and GDSC: Genomic of Drug Sensitivity in Cancer). The present study reveals that SLFN11 not only detects stressed replication but also inhibits unscheduled re-replication induced by pevonedistat, thereby enhancing its anticancer efficacy. It also suggests SLFN11 as a potential predictive biomarker for pevonedistat in ongoing and future clinical trials.
Insights
Schlafen 11 (SLFN11) is a predictive biomarker for cancer drugs. New research shows SLFN11 inhibits unscheduled re-replication caused by pevonedistat, enhancing anticancer efficacy and suggesting SLFN11 as a biomarker for pevonedistat treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Schlafen 11 (SLFN11) is a key predictive biomarker and molecular sensor for various anticancer drugs, including topoisomerase, PARP, replication inhibitors, and platinum derivatives.
- Expanding the therapeutic targets and drug spectrum associated with SLFN11 is crucial for advancing cancer treatment strategies.
Purpose of the Study:
- To identify novel drugs and pathways that target SLFN11 by conducting a high-throughput screen.
- To investigate the mechanism by which pevonedistat and AHPN/CD437 interact with SLFN11 and influence cancer cell viability.
- To establish SLFN11 as a predictive biomarker for pevonedistat in cancer therapy.
Main Methods:
- A high-throughput screen of 1,978 oncology-focused compounds was performed using isogenic cell pairs proficient and deficient in SLFN11.
- Compounds inducing selective killing of SLFN11-proficient cells were identified, including known DNA-targeting agents, pevonedistat, and AHPN/CD437.
- SLFN11 recruitment to chromatin and its role in regulating unscheduled re-replication upon pevonedistat treatment were analyzed.
Main Results:
- Twenty-nine hit compounds selectively killed SLFN11-proficient cells, including the neddylation inhibitor pevonedistat and the DNA polymerase α inhibitor AHPN/CD437.
- Pevonedistat and AHPN/CD437 induced SLFN11 chromatin recruitment, with pevonedistat showing a delayed recruitment (24 hours) compared to other agents (4 hours).
- SLFN11 inhibited pevonedistat-induced unscheduled re-replication, enhancing anticancer efficacy, and a positive correlation between SLFN11 expression and pevonedistat sensitivity was observed across multiple cancer cell databases.
Conclusions:
- SLFN11 functions not only as a sensor for replication stress but also actively inhibits unscheduled re-replication induced by pevonedistat, thereby potentiating its anticancer effects.
- The findings support SLFN11 as a potential predictive biomarker for pevonedistat, guiding its use in current and future clinical trials.
- This study expands the known drug targets and pathways influenced by SLFN11, offering new avenues for cancer therapy development.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Replicative Cell Senescence
Restarting Stalled Replication Forks
What is the Cell Cycle?

